VNVC's $79 mln vaccine plant built with international expertise

Vietnam Vaccine Joint Stock Company (VNVC) has officially signed a contract with Germany's Rieckermann Group, a world leader in vaccine and pharmaceutical plant design, to develop a state-of-the-art vaccine and biopharmaceutical production facility, Radio the Voice of Vietnam reported.

The VNVC vaccine and biopharmaceutical plant represents a significant investment of approximately VND2 trillion ($78.7 million). The facility, to be designed and constructed by Rieckermann Group, will employ cutting-edge technologies with the ambitious goal of achieving Net Zero – eliminating greenhouse gas emissions entirely.

Rieckermann has expertly optimized a 26,000 sq.m area to create a sophisticated complex, which will include vaccine and biopharmaceutical production zones, an animal breeding and research building, and additional utility areas, all conforming to the highest international standards.

The production plant will adhere to stringent GMP (Good Manufacturing Practice) standards set by the EU, FDA, PIC/S, and WHO.

Furthermore, a specialized animal laboratory will support pre-clinical and clinical trials for vaccines and biopharmaceuticals, meeting the rigorous requirements of GLP (Good Laboratory Practice) and AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) standards. These high-level standards ensure critical legal and ethical compliance.

Rieckermann boasts an impressive portfolio, having designed numerous vaccine and pharmaceutical facilities for global giants like GSK, MSD, and Roche, all built to the most stringent pharmaceutical production standards, including EU GMP, FDA, PIC/S, and WHO guidelines.